×
About 1,058 results

ALLMedicine™ Glucose Tolerance Testing Center

Research & Reviews  327 results

Mitotic CDK1 and 4E-BP1 II: A single phosphomimetic mutation in 4E-BP1 induces glucose ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004604
PloS One; Cao S, Jurczak MJ et. al.

Mar 11th, 2023 - Cyclin-dependent kinase 1 (CDK1)/cyclin B1 phosphorylates many of the same substrates as mTORC1 (a key regulator of glucose metabolism), including the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Only mitotic CDK1 phosphorylates 4E-...

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
https://clinicaltrials.gov/ct2/show/NCT02520609

Mar 10th, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in the Western world, and is a leading cause of liver-related morbidity and mortality. Excessive caloric intake and specific nutritional components have been implicated ...

Canadian Cystic Fibrosis-related Diabetes Clinical Practice Survey: Analysis of Current...
https://doi.org/10.1016/j.jcjd.2023.02.002
Canadian Journal of Diabetes; Potter KJ, Coriati A et. al.

Mar 6th, 2023 - Our aim in this study was to identify challenges and gaps in Canadian practices in screening, diagnosis and treatment of cystic fibrosis-related diabetes (CFRD), with the goal of informing a Canadian-specific guideline for CFRD. We conducted an on...

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis
https://clinicaltrials.gov/ct2/show/NCT03650712

Mar 3rd, 2023 - A. Hypotheses and Specific Aims: Cystic Fibrosis Related Diabetes Mellitus (CFRD) has been identified by the CF community as one of the top ten priorities for CF research1. In CF, clinical decline due to dysglycemia begins early, prior to the diag...

Trends in Screening for Diabetes in Early Pregnancy in the United States.
https://doi.org/10.1089/jwh.2022.0305
Journal of Women's Health (2002); Wilkie GL, Leftwich HK et. al.

Feb 17th, 2023 - Objective: The aim of this study was to characterize current diabetes screening practices in the first trimester of pregnancy in the United States, evaluate patient characteristics and risk factors associated with early diabetes screening, and com...

see more →

Drugs  16 results see all →

Clinicaltrials.gov  51 results

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
https://clinicaltrials.gov/ct2/show/NCT02520609

Mar 10th, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in the Western world, and is a leading cause of liver-related morbidity and mortality. Excessive caloric intake and specific nutritional components have been implicated ...

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis
https://clinicaltrials.gov/ct2/show/NCT03650712

Mar 3rd, 2023 - A. Hypotheses and Specific Aims: Cystic Fibrosis Related Diabetes Mellitus (CFRD) has been identified by the CF community as one of the top ten priorities for CF research1. In CF, clinical decline due to dysglycemia begins early, prior to the diag...

Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans
https://clinicaltrials.gov/ct2/show/NCT05058690

Feb 8th, 2023 - This multicentre prospective study will evaluate the ability of the FatHealth technology to correctly identify individuals with pre-diabetes and diabetes, validating the technology against the current gold-standard diagnostic method, oral glucose ...

Immediate Postpartum Glucose Tolerance Testing
https://clinicaltrials.gov/ct2/show/NCT04199676

Jan 26th, 2023 - Gestational diabetes affects approximately 5-10% of pregnancies and its prevalence continues to increase as rates of obesity and metabolic disease increase in reproductive age women. Women diagnosed with gestational diabetes carry an increased ris...

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT00445627

Jan 13th, 2023 - Background: Type 2 diabetes mellitus (T2DM) is a condition characterized by insulin resistance and progressive failure of the insulin-secreting beta-cells. Previously considered a disease of adults, it is now becoming increasingly prevalent in chi...

see more →

News  27 results

More Sleep, Fewer Calories Consumed
https://www.medpagetoday.com/neurology/sleepdisorders/97048

Feb 7th, 2022 - More sleep was linked with fewer calories consumed, a single-center randomized clinical trial showed. Compared with controls, young adults who were overweight and habitually slept less than 6.5 hours a night slept an extra 1.2 hours on average aft...

Gestational diabetes carries CVD risk years later
https://www.mdedge.com/cardiology/article/235252/cad-atherosclerosis/gestational-diabetes-carries-cvd-risk-years-later
Richard Mark Kirkner

Feb 1st, 2021 - Women who’ve had gestational diabetes are 40% more likely to develop coronary artery calcification later in life than are women haven’t, and attaining normal glycemic levels doesn’t diminish their midlife risk for atherosclerotic cardiovascular di.

In gestational diabetes, early postpartum glucose testing is a winner
https://www.mdedge.com/internalmedicine/article/218148/obstetrics/gestational-diabetes-early-postpartum-glucose-testing?channel=39313
Kari Oakes

Mar 1st, 2020 - GRAPEVINE, TEX. – Early postpartum glucose tolerance testing for women with gestational diabetes resulted in a 99% adherence rate, with similar sensitivity and specificity as the currently recommended 4- to 12-week postpartum testing schedule.

In gestational diabetes, early postpartum glucose testing is a winner
https://www.mdedge.com/obgyn/article/218148/obstetrics/gestational-diabetes-early-postpartum-glucose-testing-winner
Kari Oakes

Mar 1st, 2020 - GRAPEVINE, TEX. – Early postpartum glucose tolerance testing for women with gestational diabetes resulted in a 99% adherence rate, with similar sensitivity and specificity as the currently recommended 4- to 12-week postpartum testing schedule.

Teplizumab delays onset of type 1 diabetes
https://www.mdedge.com/pediatrics/article/202556/diabetes/teplizumab-delays-onset-type-1-diabetes
Bianca Nogrady

Jun 9th, 2019 - The monoclonal antibody teplizumab may delay the onset of type 1 diabetes in individuals at high risk, according to research presented at the annual scientific sessions of the American Diabetes Association. In this study, 76 first-degree relatives.

see more →

Patient Education  2 results see all →